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Abstract
Liver transplantation (LT) is the only potentially curative treatment for selected
patients with cirrhosis and hepatocellular carcinoma (HCC) who are not
candidates for resection. When the Milan criteria are strictly applied, 75% to
85%of 3- to 4-year actuarial survival rates are achieved, but up to 20% of the
patients experience HCC recurrence after transplantation. The Milan criteria are
based on the preoperative tumor macromorphology, tumor size and number on
computed tomography or magnetic resonance imaging that neither correlate well
with posttransplant histological study of the liver explant nor accurately predict
HCC recurrence after LT, since they do not include objective measures of tumor
biology. Preoperative biological markers, including alpha-fetoprotein, des-
gamma-carboxiprothrombin or neutrophil-to-lymphocyte ratio and platelet-to-
lymphocyte ratio, can predict the risk for HCC recurrence after transplantation.
These biomarkers have been proposed as surrogate markers of tumor
differentiation and vascular invasion, with varied risk magnitudes depending on
the defined cutoffs. Different studies have shown that the combination of one or
several biomarkers integrated into prognostic models predict the risk of HCC
recurrence after LT more accurately than Milan criteria alone. In this review, we
focus on the potential utility of these serum biological markers to improve the
performance of Milan criteria to identify patients at high risk of tumoral
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Core tip: The Milan criteria for liver transplantation have improved survival of patients
with small hepatocellular carcinoma (HCC), but up to 20% of patients still experience
HCC recurrence after transplantation. Microvascular invasion and tumors with poor
histologic grade of differentiation are the most important risk factors for HCC
recurrence, but they are evidenced after surgery on explant pathology examination.
Several surrogate pretransplant biomarkers, directly related with tumor biology or
systemic inflammation markers conditioning tumor progression, have been suggested to
identify, alone or integrated in pretransplant prognostic scores, patients at high risk of
HCC recurrence after liver transplantation.
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of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019;
11(1): 50-64
URL: https://www.wjgnet.com/1948-5182/full/v11/i1/50.htm
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INTRODUCTION
Liver transplantation (LT) is  the best  treatment option for selected patients with
cirrhosis  and small  hepatocellular  carcinoma (HCC) who are  not  candidates  for
resection.  Mazzaferro  et  al[1]  proposed the  Milan criteria  in  1996  for  selection of
patients with HCC for LT (defined as single lesion ≤ 5 cm, up to three separate lesions
with none larger than 3 cm, no evidence of gross vascular invasion, and no regional
nodal  or  distant  metastases),  and since then they have been applied worldwide.
Patients fulfilling these criteria achieve similar survival rates as patients with LT
without malignancies, of about 75% to 85% at 3 and 4 years respectively[2]. However,
albeit  that  the  Milan  criteria  are  considered  too  restrictive  and  limiting  for  the
transplantation  option,  HCC  recurrence  develops  after  LT  in  up  to  20%  of  the
patients[1-3], having adverse negative impact on patient survival. A poor histologic
grade of differentiation, presence of vascular invasion, nodule size of > 5 cm, lymph
nodes metastases and bilobar tumor involvement are classically associated with an
increased risk of HCC recurrence after LT.
The Milan criteria  are  based on the preoperative tumor macromorphology on
computed tomography or magnetic resonance imaging, that neither correlate well
with posttransplant histologic study of the liver explant[4,5] nor accurately predict HCC
recurrence after LT, since they do not include objective measures of tumor biology. In
fact, small HCC may present biological aggressive features with unfavorable post-LT
outcome, while other patients with HCC beyond Milan criteria but fulfilling the
University of California San Francisco (UCSF) criteria[6] or the Up-to-7 criteria[7] could
have a low risk of HCC recurrence in the presence of favorable tumor biology and
could benefit from LT.
Liver biopsy is still the gold standard for determining the molecular biology of the
tumor, its behavior and invasive characteristics. Some centers deny LT to patients
with poorly differentiated tumors on needle biopsy, irrespective of number and size
of tumoral nodules, and they have reported an excellent overall survival and low
recurrence rates after  LT even in patients exceeding Milan criteria[8-10].  However,
preoperative biopsy often underestimates poorly differentiated tumors and does not
accurately predict microvascular invasion, when compared with the final specimen
examination after liver resection or LT[11,12]. Due to these limitations and because of the
risk of needle tract tumor seeding, preoperative biopsy is not currently recommended
for routine HCC evaluation;  although, it  is  still  needed in patients with atypical
radiological features and in doubtful cases.
Preoperative  biological  markers  can  predict  the  risk  for  recurrence  after
transplantation. Biological markers can be categorized as: (1) serum markers directly
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related  with  tumor  biology,  such  as  alpha-fetoprotein  (AFP)  and  des-gamma-
carboxyprothrombin  (DCP);  or  (2)  systemic  inflammation  markers,  such  as
neutrophil-to-lymphocyte  ratio  (NLR)  and  platelet-to-lymphocyte  ratio  (PLR)
conditioning tumor progression. In this review, we focus on the utility of these serum
biological  markers  to  improve  the  performance  of  Milan  criteria  for  predicting
recurrence after LT for HCC.
SERUM BIOLOGICAL MARKERS RELATED WITH TUMOR
BIOLOGY
AFP
AFP is a 67-kDa glycoprotein that is produced by the liver in early fetal life. In adults,
AFP production is restricted to a variety of liver tumors, including HCC, because of
the dedifferentiation of  hepatocytes.  First  considered a reliable  marker for  HCC
diagnosis, at present the joined committees of the European Association for the Study
of the Liver (commonly known as EASL) and the European Organization for Research
and Treatment of  Cancer (commonly known as EORTC) consider AFP testing as
suboptimal for routine screening of early HCC (2B)[13].  In fact, about 80% of small
HCC (< 2 cm) do not show high levels of serum AFP[14,15]. In the other hand, AFP level
can be increased in patients with chronic liver disease, with a degree of hepatocytes
regeneration in absence of malignancy[16].
Nevertheless,  AFP is a surrogate marker of tumor differentiation and vascular
invasion[17-20] and has proven a useful biomarker to identify patients at a higher risk for
HCC recurrence[21],  with  varied risk  magnitudes  depending on the  defined AFP
cutoffs[22-33]. AFP has been integrated into several prognostic models for predicting
recurrence after LT for HCC, by combining AFP level with tumor size and number, at
different cutoffs for each variable (Table 1).  Integration of AFP into the selection
criteria  was  first  proposed for  patients  receiving living donor  (LD)  LT in  Asian
countries,  since  the  fast-track  to  LDLT may result  in  inclusion  of  patients  with
biologically aggressive HCC.
In the score proposed by Yang et  al[34]  patients were awarded between 1 and 4
points for each feature, with three different cutoffs: tumor size of 3, 5 and 6.5 cm;
tumor number = 1, 3 and 5; and, AFP of 20, 200 and 1000 ng/mL. With a maximum
score of 12 points, patients with a score ≥ 7 were considered as nontransplantable
patients. In contrast, the Hangzhou criteria[35] consider transplantable patients as those
with well or moderately differentiated HCC and having a total tumor diameter of > 8
cm and AFP of < 400 ng/mL. A large study conducted in 6487 patients registered in
the Scientific Registry of Transplant Recipients database[36] showed that total tumor
volume of ≤ 115 cm3 and pretransplant AFP of ≤ 400 ng/mL identified patients at low
risk of  HCC recurrence after  LT more effectively than both the Milan and UCSF
criteria. This prognostic score has been validated both retrospectively in Poland[37] and
prospectively in a multicenter study carried out in Canada,  Switzerland and the
United Kingdom[38].
The  Liver  Transplantation  French  Study  Group  developed  and  validated  a
prognostic model, known as the AFP model, for predicting recurrence after LT that
combines AFP level, tumor size and number, at different cutoffs for each variable[17].
Tumor size was assigned: 0, 1 or 4 points when the largest tumor size was ≤ 3 cm,
between 3-6 cm or ≥ 6 cm respectively; 0 or 2 points for ≤ 3 nodules or ≥ 4 nodules;
and, AFP level added 0, 2 or 3 points for AFP ≤ 100, between 100-1000 or > 1000
ng/mL respectively; with a maximum score of 9 points. A cutoff of 2 points classified
patients at low or high risk for HCC recurrence after LT. Thus, AFP > 1000 ng/mL
provides enough points for excluding patients from LT whatever the size and number
of nodules.
The AFP model better  discriminated patients at  high and low risk than Milan
criteria. This model identifies patients within Milan criteria but with high risk of 5-
year HCC recurrence as those having AFP > 1000 ng/mL (37.7% vs  13.3%), while
patients beyond Milan criteria but with AFP < 100 have a low risk of HCC recurrence
(14.4% vs 47.6%). Indeed, this model has been officially adopted in the liver allocation
policy in France since 2013. This score has been validated in a single center from
Spain[39]  and  in  two  multicenter  studies,  respectively  from  Italy[20]  and  Latin
America[40], with similar results. Moreover, the AFP model has also been validated in a
cohort  of  400  patients  with  LDLT  from  Korea,  in  whom  this  model  showed  an
improvement  in  predicting  no  HCC  recurrence  but  not  the  occurrence  of  HCC
recurrence[41].
All these models have been proved successful for selecting patients beyond the
Milan criteria who will achieve similar outcomes to patients within Milan criteria.
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Table 1  Main selection criteria for liver transplantation including alpha-fetoprotein
Reference Country n AFP cutoff, ng/mL Criteria Validated in
Yang et al[34], 2007 Korea 63 20, 200 and 1000 Tumor number, tumor
size and AFP level with
different cutoffs
Zheng et al[35], 2008 China 195 400 Hangzhou criteria: (1)
TTD ≤ 8 or (2) TTD > 8,
well or moderately
differentiated and AFP
< 400
Toso et al[36], 2009 SRTR database 6487 400 TTV/AFP criteria for
overall survival after LT:
TTV ≤ 115cm3 and AFP
≤ 400
Validated for recurrence
after LT: Grat et al[37],
2013; Toso et al[38],2015.
Duvoux et al[17], 2012 France 537 (training cohort);
435 (validation cohort)
100 and 1000 AFP model: tumor
number, tumor size and
AFP level with different
cutoffs
Varona et al[39], 2015;
Notarpaolo et al[20], 2017;
Piñero et al[40], 2016; Rhu
et al[41], 2018
Lai et al[45], 2012 Italy 158 400 AFP-TTD criteria: TTD
< 8 cm and AFP < 400
Grąt et al[42], 2014 Poland 101 100 Warsaw criteria: (I)
fulfillment of Milan
criteria; or (II) Up-to-7
or UCSF criteria and
AFP < 100
Piñero et al[43], 2016;
Grat et al[44], 2017
Kim et al[46], 2014 Korea 180 1000 Samsung criteria: Up to
7 tumors ≤ 6 cm, and
AFP ≤ 1000
AFP: Alpha-fetoprotein; LT: Liver transplantation; SRTR: Scientific Registry of Transplant Recipients; TTD: Total tumor diameter; TTV: Total tumor
volume; UCSF: University of California San Francisco.
Also, in a recent study[42] evaluating the role of AFP as predictor of HCC recurrence
with respect to the fulfillment of Milan, UCSF or Up-to-7 criteria, patients beyond
Milan criteria but within UCSF or Up-to-7 and with AFP < 100 ng/mL had a minimal
risk of HCC recurrence after LT, criteria that have been validated in other studies[43,44].
Albeit AFP has proved to be a useful biomarker for identifying patients at a higher
risk for  HCC recurrence,  there is  no consensus about the best  cutoff  value to be
considered. While different cutoffs have been proposed in several scores[17,34], other
criteria  include  a  sole  cutoff  at  400  ng/mL[35,36,45]  or  1000  ng/mL[46].  Also,  serial
measurements of AFP (accounting for AFP variations) have been considered to better
reflect the dynamic variations in the tumor biological behavior than a cutoff value of
AFP level in a single assessment. Progression of AFP level while on the waiting list
exceeding 15 ng/mL per mo[47,48], 50 ng/mL per mo[49] or 0.1 ng/mL per d[50] have been
suggested as strong predictors of HCC recurrence after LT. In contrast, Grąt et al[42]
found AFP > 100 ng/mL to better identify patients at risk of HCC recurrence than
AFP slope.
DCP
Increased levels of DCP or prothrombin induced by vitamin K absence or antagonist
II  (PIVKA-II)  are  found  in  patients  with  HCC [51-43].  This  abnormal  form  of
prothrombin, produced during malignant transformation of hepatocytes, induces
expression of  angiogenic  factors  such as  endothelial  growth factor  receptor  and
vascular endothelial growth factor (VEGF)[54,55]. Up-regulation of DCP has been found
to correlate  with the degree of  malignancy of  HCC, as  DCP-positive tumors are
characterized by increased likelihoods of intrahepatic metastasis, capsule infiltration,
and portal  venous  invasion[56,57].  Moreover,  the  DCP-positive  and AFP-negative
tumors are more aggressive, for high risk of recurrence after treatment, since they are
usually larger tumors with a poor grade of differentiation and vascular invasion[58,59].
DCP has been suggested as a stronger predictor of HCC recurrence after LT than
AFP[57,60] and some centers from Asia have proposed the combined use of DCP level
with tumor number and/or size in selection of candidates for LDLT with or without
consideration  of  the  AFP value  (Table  2).  The  Kyoto  criteria[61]  and the  Kyushu
criteria[62] have been retrospectively and prospectively validated in the same centers
where these scores were proposed[63-65]. Patients beyond Milan criteria but meeting
Kyoto criteria had similar recurrence rate as patients within Milan criteria[61], while
WJH https://www.wjgnet.com January 27, 2019 Volume 11 Issue 1
Citores MJ et al. Biomarkers of posttransplant HCC recurrence
53
Kyushu  criteria  was  more  powerful  than  UCSF,  Tokyo  and  Kyoto  criteria  in
predicting HCC recurrence[65].
Other centers have proposed different scores combining AFP and DCP levels with
different cutoffs for both serum biomarkers that have improved Milan criteria for
selection of patients at higher risk of HCC recurrence after LT. The A-P level criteria[66]
included AFP ≤ 200 ng/mL “and” DCP ≤ 100 AU/mol, while the A-P 200 criteria[67]
considered AFP ≤ 200 ng/mL “or” DCP ≤ 200 AU/molto identify patients at lower
risk of HCC recurrence. Kim et al[68] found AFP > 150 ng/mL and DCP > 100 AU/mol
to be associated with a higher risk of HCC recurrence after LT.
Lee  et  al[69]  from  Seoul,  Korea  developed  and  validated  a  model  to  predict
recurrence after LDLT for HCC beyond the Milan criteria. Using a multivariate Cox
proportional hazard model, the authors derived the model of recurrence after LT
(commonly known as MoRAL) score using serum levels of AFP and DCP. Patients
with a low MoRAL score (≤ 314.8) and no extrahepatic metastasis, even though their
tumors exceeded the Milan criteria, had a lower tumor recurrence risk than patients
within the Milan criteria with a high MoRAL score (> 314.8). Finally, the only study
carried out in a non-Asiatic center found AFP ≥ 250 ng/mL and DCP ≥ 7.5 ng/mL to
be  associated  with  a  higher  risk  of  HCC  recurrence[70],  and  added  predictive
information to the Milan criteria [hazard ratio (HR): 4.5 vs  2.6 with Milan criteria
alone].
SYSTEMIC INFLAMMATION MARKERS
NLR and PLR
Two  inflammation  markers,  the  NLR  and  the  PLR,  have  an  important  role  in
predicting outcome in several  malignancies and have been associated with HCC
recurrence after LT. Both the NLR and the PLR measure the proportion of peripheral
blood neutrophils or platelets, respectively, to lymphocytes.
The link between NLR and liver malignancies was first demonstrated by Halazun
et al[71] in patients who underwent surgery for colorectal liver metastasis. Same authors
also reported that patients within Milan criteria and NLR ≥ 5 had a poorer recurrence-
free survival than those with NLR < 5 (25% vs 75%) and proposed a pre-LT score for
HCC recurrence after LT including NLR and tumor size > 3 cm (C-statistics: 0.74)[72].
Since then, NLR has been identified as an independent risk factor for HCC recurrence,
along  with  microvascular  invasion  and/or  tumor  size  and  number  in  some
studies[73-77], but not in others[78-80]. A recent systematic review by Najjar et al[81] and a
meta-analysis by Xu et al[82]  showed that elevated NLR is associated with a lower
recurrence-free  survival  after  LT  (pooled  HR:  3.77,  95%CI:  2.01-7.06)  and  with
vascular invasion. Because of the different NLR cutoffs considered in the studies
included in the meta-analysis (ranging from 2.6 to 6), Xu et al[82] recommend a cutoff
NLR value of 4.
The prognostic  significance of  PLR for HCC recurrence after  LT has been less
extensively studied than that of NLR, but in a recent systematic review and meta-
analysis including 899 patients from five studies, high PLR was associated with a
significant increase of HCC recurrence after LT[83]. However, this association must be
taken in consideration with great caution since a moderate level of heterogeneity was
found among the studies included. In a recent study by Xia et al[84],  PLR failed to
predict HCC recurrence in patients meeting Milan criteria, but the 5-year recurrence-
free  survival  in  patients  with  HCC beyond Milan criteria  but  within  Hangzhou
criteria (total tumor diameter of ≤ 8 cm or > 8 cm, well or moderately differentiated
and pretransplant AFP of < 400 ng/mL and PLR < 120) was comparable to the figure
for patients within Milan criteria (73.3% vs 72.8%).
Han et al[85] also found that PLR was associated with HCC recurrence after LT, but
interestingly a stronger association was found when considering the absolute platelet
count. HCC recurrence rate after LT was higher in patients with platelet count of 75 ×
109/L or greater at the day before surgery compared to patients with platelet count
lower  than  75  ×  109/L  (28.2%  vs  13.2%).  Moreover,  the  proportion  of  poorly
differentiated tumors, microvascular invasion and bile duct invasion were higher in
patients  with  platelet  count  of  75  ×  109/L or  greater.  In  the  experience  of  those
authors,  the  incorporation  of  platelet  count  at  75×109/L  into  the  Milan  criteria
significantly increased the predictive power for HCC recurrence, over that of Milan
criteria alone.
The molecular mechanisms through which the NLR and PLR are associated with
HCC  recurrence  after  LT  remain  unknown,  but  several  hypotheses  have  been
proposed.  Both neutrophils  and platelets  are  involved in  vascular  invasion and
metastatization  by  increasing  the  production  of  proangiogenic  factors  such  as
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Table 2  Main selection criteria for liver transplantation including des-gamma-carboxyprothrombin
Reference Country n Cutoff values Criteria Validated in
Takada et al[61],2007 Japan 125 DCP: 400 Kyoto criteria: up to
10 tumors ≤ 5 cm
and DCP ≤ 400
Fujiki et al[63], 2009;
Kaido et al[64], 2013
Soejima et al[62],
2007
Japan 60 DCP: 300 Kyushu criteria: any
number of tumors <
5 cm and DCP < 300
Shirabe et al[65], 2011
Todo et al[66], 2007 Japan 551 AFP:200, DCP: 100 A-P level: AFP ≤ 200
and DCP ≤ 100
Chaiteerakij et al[70],
2015
United States 127 AFP:250, DCP: 7.5
Yang et al[67], 2016 Korea 88 (training cohort);
198 (validation
cohort)
AFP: 200; DCP: 200 A-P 200: AFP ≤ 200
or DCP ≤ 200
Kim et al[68], 2016 Korea 461 AFP: 150; DCP:100 --
AFP: Alpha-fetoprotein; DCP: Des-gamma-carboxyprothrombin; MoRAL: Model of recurrence after liver transplantation.
VEGF[86,87].  Moreover, neutrophils, the common inflammatory infiltrate in tumors,
have been found to be enriched predominantly in the peritumoral stroma of HCC
tissue[75,88],  correlating  with  angiogenesis  and disease  progression[89].  Within  the
circulatory system, platelets could help to establish metastatic lesions by blocking
tumor cell removal[90,91].  On the other hand, low lymphocyte numbers, which also
increase  NLR and PLR values,  could result  in  an impaired immunosurveillance
against disease development and progression.
C-reactive protein
The C-reactive protein (CRP) is an acute-phase reactant synthesized by hepatocytes in
response to systemic inflammation that has been related with the prognosis of various
malignancies, including HCC[92]. Two independent groups from Korea have reported
that  high  CRP  level  (with  cutoff  values  at  1  mg/dL[93]  or  0.3  mg/dL[94])  is  an
independent risk factor for HCC recurrence after LT, but only in patients beyond
Milan criteria.
COMBINATION OF SERUM BIOLOGICAL MARKERS
In recent years, several studies have showed that the combination of several systemic
inflammation biomarkers and tumor biomarkers predict the risk of HCC recurrence
after  LT  more  accurately  (Table  3).  In  all  the  nine  studies  summarized,  the
relationship  among  tumor  features  and  HCC  recurrence  was  evidenced,  and
interestingly all studies analyzing pre-LT AFP level, except for one[95], found AFP to be
an independent risk factor for HCC recurrence[80,96-98].  Also, Lai et al[78]  found that
although AFP and PLR were associated with HCC recurrence in univariate analysis,
AFP > 200 ng/mL was the best prognostic factor with an area under the receiver
operating characteristic curve (AUC) of 70.6 compared to 66.1 for PLR. Similarly, only
two  studies[80,99]  out  of  three,  found  DCP  to  be  an  independent  factor  for  HCC
recurrence.
Regarding the systemic inflammation markers, NLR was found to be associated
with HCC recurrence in six[82,95-99] out of nine studies and CRP in one[96] of two studies,
while PLR was not shown as an independent risk factor in any of the four studies in
which it was analyzed[78,79,99,100]. The two studies that analyzed inflammation marker
sonly, found none of the biomarkers included to be independent risk factors for HCC
recurrence[79,100]. Parisi et al[79] analyzed NLR, PLR and the inflammation-based index
score (CRP ≥ 10 mg/dL and albumin < 35 gr/L; one point each) in 150 patients within
Milan criteria before LT and found that absence of neoadjuvant therapy before LT and
exceeding Milan criteria on explant pathology were the only risk factors for HCC
recurrence. Fu et al[100] investigated the prognostic role of the systemic inflammation
index (SII; absolute platelet count × absolute neutrophil count/absolute lymphocyte
count)  compared with  PLR,  NLR and monocyte-to-lymphocyte  ratio  in  patients
fulfilling the Hangzhou criteria for LDLT. At a cutoff of 226 × 109/mL, high SSI was
associated with larger tumor size, greater total tumor volume, poorer differentiation
grade and higher AFP level. Nevertheless, although SII was the best prognostic factor
for  overall  survival,  neither  SSI  nor  the  other  systemic  inflammatory  markers
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Table 3  Main studies analyzing several pre-liver transplantation systemic inflammation biomarkers and proposed scores
Reference Country LT type n Biomarkers Time ofbiomarker test
Risk factors by
multivariate
analysis
Risk score
Yoshizumi et
al[95], 2013
Japan LDLT 104 AFP > 400, DCP >
300, NLR ≥ 4
Not specified NLR, tumor size
+ number ≥ 8
No
Na et al[96], 2014 Korea LDLT 224 AFP ≥ 100, NLR ≥
6, CRP ≥ 1,
Day of LT NLR ≥ 6 and AFP
≥ 100
Prognostic factor
score: NLR ≥ 6
and CRP ≥ 1 (one
point each)
Shindoh et al[80],
2014
Japan LDLT 124 AFP, DCP, NLR Day before LT,
maximum and
mean values
within 90 d before
LT
Tumor ≥ 5, MVI,
mean NLR and
maximum AFP
and DCP before
LT
Tokyo criteria,
AFP > 250 and
DCP > 450 (one
point each)
Lai et al[78], 2014 Belgium DDLT 146 AFP > 200, NLR >
5.4, PLR > 150
At inclusion on
the waiting list, at
LT,
AFP, NLR and
PLR in univariate
analysis
No
Parisi et al[79],
2014
UK DDLT 150 NLR ≥ 5, PLR ≥
150, IBI score
Day of LT Absence of
neoadjuvant
therapy, beyond
Milan criteria on
explant
No
Harimoto et
al[99], 2016
Japan LDLT 190 DCP ≥ 300, NLR ≥
2.66, PLR ≥ 70.4,
CRP ≥ 0.27
Not specified NLR, DCP, and
tumor number ≥ 5
No
Wang et al[97],
2016
China DDLT/LDLT 248 NLR continuous,
AFP > 400
Within 1 wk
before LT
NLR , AFP > 400,
age, tumor
number and size
Model TFS: 1.094
× tumor number
(≤ 3, 0 points; > 3
(1 point) + 0.094 ×
maximum tumor
diameter + 0.754
× AFP (≤ 400, 0
points; > 400, 1
point) + 0.085 ×
NLR -0.024 × age
Halazun et al[98],
2017
United States DDLT/LDLT 339 NLR ≥ 5, AFP NLR at day of LT;
serial AFP at
HCC diagnosis,
before pre-LT
treatment and at
LT.
Tumor size and
number, NLR ≥ 5,
maximum pre-LT
AFP, vascular
invasion and poor
differentiated
tumors
MoRAL score: (1)
pre-MoRAL: NLR
≥ 5 (6 points) +
AFP > 200 (4
points) + largest
tumor size > 3 cm
by imaging (3
points); (2) post-
MoRAL: grade IV
tumors (6 points)
+ vascular
invasion (2
points) + tumor
size > 3 on
pathology (3
points) + tumor
number > 3 on
pathology (2
points); and (3)
combined score.
Fu et al[100], 2018 China LDLT 150 NLR, PLR, MLR,
SII
Within 1 wk
before LT
No association No
AFP: Alpha-fetoprotein; CRP: C-reactive protein; DCP: Des-gamma-carboxyprothrombin; DDLT: Deceased donor liver transplantation; IBI: Inflammation
based index; LDLT: Living donor liver transplantation; LT: Liver transplantation; MVI: Microvascular invasion; NLR: Neutrophil-to-lymphocyte ratio;
PLR: Platelet-to-lymphocyte ratio; SII: Systemic inflammation index; TFS: Tumor-free survival.
analyzed were associated with recurrence-free survival.
Prognostic scores including inflammatory markers for HCC recurrence after LDLT
have been proposed by three different groups from Asia and one group from the
United States. Na et al[96] proposed a prognostic factor score assigning 1 point for pre-
LT NLR ≥ 6 and CRP ≥ 1 each, and Wang et al[97], who included only males receiving a
LDLT, proposed the model tumor free survival,  combining tumor morphological
features  with  tumor  biological  information.  Interestingly,  both  scores  were
WJH https://www.wjgnet.com January 27, 2019 Volume 11 Issue 1
Citores MJ et al. Biomarkers of posttransplant HCC recurrence
56
informative  only  in  patients  beyond  Milan  criteria,  and  not  predictive  of  HCC
recurrence in patients within Milan criteria.
The score proposed by Shindoh et al[80]  incorporates pre-LT maximum AFP and
DCP in the Tokyo criteria (≤ 5 tumors of ≤ 5 cm) to better stratify patients at risk of
HCC recurrence after LT. After evaluating three different pre-LT values for NLR, AFP
and DCP (the last value before LT, and the maximum and mean values within the 90
d before LDLT), the maximum AFP and DCP values and the mean value of NLR were
independently  associated  with  HCC  recurrence.  However,  NLR  had  a  limited
prognostic  impact  (AUC:  0.62)  and  only  maximum  AFP  and  DCP  values  had
sufficient discriminative power (AUC: 0.88 and 0.76 respectively). So, the authors
proposed extending the Tokyo criteria by adding AFP > 250 and DCP > 450 (1 point
for each variable; maximum score of 3). Patients with a score 0-1 had a 5-year disease-
free survival rate of 97%, opposed to only 20% of patients with a score 2-3.
In 2017, Halazun et al[98] carried out a prospective study of 339 patients to identify
predictors of HCC recurrence after LT. Preoperative NLR > 5 (P < 0.0001, HR: 6.2),
AFP > 200 (P < 0.0001, HR: 3.8) and tumor size > 3 cm (P < 0.001, HR: 3.2) were found
to be independently associated with a worse recurrence-free survival. The authors
developed a new MoRAL score for predicting HCC recurrence after LT, mainly in
individuals receiving a liver from deceased donors[98]. They constructed three scores:
the  pre-MoRAL,  the  post-MoRAL  and  the  combined-MoRAL  score,  the  latter
including both pre-MoRAL and post-MoRAL scores. The pre-MoRAL score, included
the three preoperative significant variables with a minimum of 0 points (no factors)
and a maximum of 13 points  (all  3  factors).  The highest  risk patients  in the pre-
MoRAL (score > 10) had a 5-year recurrence-free survival of 17.9% compared with
98.6% for  the low risk group (P  <  0.0001).  The post-MoRAL score included four
postoperatively available factors related to pathological features in liver explant,
namely grade 4 HCCs, vascular invasion, tumor size > 3 cm and tumor number > 3.
The pre-MoRAL, post-MoRAL and combo-MoRAL better predicted HCC recurrence
after LT than Milan criteria with C-statistics of 0.82, 0.87 and 0.91 respectively.
LIMITATIONS OF PRETRANSPLANT SERUM BIOMARKERS
Most of the studies to date have been retrospective and include a small sample size;
moreover, the included patients in the different studies are highly heterogeneous
regarding indications for LT, handling of incidental tumors or inclusion of salvage LT.
Also, frequent exclusion of patients who died within 1 mo or even 3 mo after LT could
have restricted data  about  the  most  aggressive  tumors.  Besides,  there  is  a  great
variation of time elapsed between the measurement of the markers and LT. Most
studies considered these markers from the analytical data of the day before LT, while
others considered these values within 1 wk before LT or did not specify it. Also, there
is no consensus about the best cutoff value for each biomarker, and it maybe those
different cutoffs should be considered in different populations or centers. In addition,
comparison of results from multiple laboratories is uncertain because of different
laboratory  methods  and processing techniques  for  measuring these  biomarkers.
Another limitation of the different studies reviewed here relies on the analyses of
HCC recurrence as a time-dependent variable, such as recurrence or disease-free
survival, without accounting for competing risk, such as death. So, patients who died
early after LT or whose death was not related to HCC may never have had the chance
to experience HCC recurrence.
Albeit the serum markers reviewed here are potential markers to be included in
patient selection for LT, their utility is limited and they cannot be universally applied
in all patients. Although AFP is considered the most useful pretransplant marker of
HCC recurrence after LT, its utility is restricted by the existence of non-AFP secreting
HCC. More restricted is the utility of systemic inflammatory markers, for different
reasons. Although some meta-analyses have suggested NLR[82] and PLR[83] as useful
pretransplant  biomarkers  for  HCC  recurrence,  they  are  based  on  very  few
retrospective studies (four and five studies respectively), with most having small
sample size. However, the most important limitation may be that these inflammatory
serum biomarkers  can  be  affected  by  other  conditions,  such  an  acute  infection,
hematologic disorders, hypersplenism, gastrointestinal tract bleeding or systemic
inflammatory diseases, which are frequent in patients with end-stage liver diseases.
OTHER POTENTIAL SERUM BIOMARKERS
In addition to the serum biomarkers reviewed here, some other markers have been
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proposed as potential risk factors for HCC recurrence after LT.
AFP-L3%,  which represents  a  serum AFP fraction reactive with lens  culinaris
agglutinin, has been associated with HCC diagnosis[101,102]. In the LT context, an AFP-
L3% level  >  50  ng/mL combined with Milan criteria  improved HCC recurrence
prediction, when compared with Milan criteria alone[70]. Interestingly, AFP-L3% has
been suggested as a highly specific marker of HCC in patients with low AFP level[102],
which could overcome the  limitation of  AFP usefulness  as  a  biomarker  of  HCC
recurrence in patients with AFP-negative HCC. However, more studies are needed for
this promising biomarker.
Liquid biopsy has attracted much attention as a feasible and noninvasive tool to
identify tumoral markers in peripheral blood for diagnosis, monitoring and prognosis
of cancer, overcoming tissue biopsy limitations. Circulating tumoral cells and tumoral
cell free nucleic acids in peripheral blood could be advisory of micro metastasis, and
their utility has been explored in HCC diagnosis and prognosis[103]. Very few data are
available  about  the  potential  role  of  these  circulating  tumoral  components  as
preoperative predictors of HCC recurrence after LT, and it is still a controversial issue.
Although circulating HCC cells have been detected before LT, they have not been
associated with HCC recurrence after LT[104]. Regarding circulating nucleic acids, AFP
mRNA  expression  in  peripheral  blood  has  been  suggested  as  a  surrogate  of
circulating tumoral  cells  and has been associated with an increased risk of  HCC
recurrence after  LT[105].  However,  their  utility  is  controversial  and some authors
consider AFP mRNA to be nonspecific for HCC micro metastases.
Some other circulating RNA have been explored, but none of them has been widely
recognized as valuable marker of HCC recurrence, probably because none of them are
specific for HCC[103]. Circulating tumor DNA has been isolated in patients with HCC,
and has been associated with microvascular invasion[106]. However, much effort is still
needed in order to consider these circulating tumor components as valuable markers
in clinical practice since some limitations still need to be overcome. Although the
complex  methodology  to  isolate  these  tumoral  components  has  improved
dramatically,  their  extremely  low frequencies  in  peripheral  blood require  more
sensitive and cost effective techniques. Also, HCC-specific biomarkers should be
validated and evidence of their association with HCC recurrence after LT should be
proven.
Finally, different micro (mi) RNA signatures in liver tissue have been associated
with HCC recurrence after LT[107,108]. However, the necessity of liver tissue samples
limits their application preoperatively, and circulating miRNAs are at present being
explored. Several circulating miRNAs have been suggested as potential biomarkers
for HCC diagnosis[109], vascular invasion and prognosis[110,111]. To date, to the best of
our  knowledge,  there  is  no  data  about  the  association  of  miRNAs  with  HCC
recurrence after LT, and future studies are warranted to explore the utility of these
promising biomarkers in preoperative prediction of HCC recurrence after LT.
CONCLUSION
Although the Milan criteria have improved survival of patients receiving a LT for
small HCC, tumor recurrence after transplantation still  develops in about 15% of
patients. On the other hand, patients with less aggressive tumors and at lower risk of
recurrence  have  proven  benefit  of  LT.  Since  the  Milan  criteria  are  based  on
morphological  tumor  feature  sonly,  combination  of  these  criteria  with  other
preoperative available biomarkers related with tumor biology could better predict
HCC recurrence after LT. Some serum biomarkers have been proposed but there is no
consensus about their use, mainly due to the several limitations commented on in this
review.  In addition,  considering that  tumor growth patterns are  highly variable
among individuals, there probably is no perfect single biomarker for HCC prognosis
after LT; thus, the combination of biomarkers could be more informative than any
single biomarker alone.
For  those  reasons  and  taking  into  account  the  limitations  highlighted  here,
multicenter prospective studies are demanded and an international consensus is
mandatory  in  order  to  provide  practical  recommendations  to  guide  the
implementation of serum biomarkers combined with morphological criteria to better
stratify patients at high or low risk of HCC recurrence after LT.
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